Lesko Catherine R, Fojo Anthony T, Hutton Heidi E, Falade-Nwulia Oluwaseun O, Zalla Lauren C, Seamans Marissa J, Jones Joyce L, Schweizer Nicholas P, Moore Richard D, Snow LaQuita N, Keruly Jeanne C, Chander Geetanjali
Johns Hopkins Bloomberg School of Public Health.
Johns Hopkins School of Medicine, Baltimore, MD.
AIDS. 2025 Mar 15;39(4):414-423. doi: 10.1097/QAD.0000000000004074. Epub 2024 Nov 25.
To estimate the effect of antidepressant initiation on viral nonsuppression among people with HIV (PWH) with clinically recognized, untreated depression.
Retrospective, observational cohort study.
We included clinical diagnoses of depression from January 2012 to June 2022 among PWH in the Johns Hopkins HIV Clinical Cohort without another serious psychiatric illness who had initiated antiretroviral therapy. We excluded diagnoses less than 90 days from a prior diagnosis, antidepressant prescription, or greater than one mental health visits. We estimated the association between initiating an antidepressant within 1 month of the index depression diagnosis and viral load nonsuppression (>200 copies/ml) on the first viral load 3-12 months subsequent. We adjusted for a comprehensive set of demographic and clinical confounders.
We included 2346 depression diagnoses among 946 patients; patients initiated an antidepressant following 16%. The risk of viral nonsuppression in the absence of antidepressant treatment was 15.6% [95% confidence interval (CI): 13.1-18.4]. Antidepressant initiation was not associated with viral nonsuppression (risk difference: 0.5%; 95% CI: -3.7 to 4.8) or secondary outcomes: improvement or resolution of depressive symptoms or adherence to scheduled clinic visits.
In this sample of patients with as-yet-untreated depression, in a setting with co-located, low-barrier psychiatric services, antidepressant treatment was not associated with improved viral suppression. Pharmacologic management of depression has documented benefits in other studies. However, there may be a subset of PWH with depression who have been previously unsuccessfully treated with antidepressants who are less likely to respond to approved pharmacologic options and who require different interventions to improve their viral suppression.
评估在患有临床确诊的未治疗抑郁症的艾滋病毒感染者(PWH)中,开始使用抗抑郁药对病毒未被抑制的影响。
回顾性观察队列研究。
我们纳入了2012年1月至2022年6月期间约翰霍普金斯艾滋病毒临床队列中开始抗逆转录病毒治疗且无其他严重精神疾病的PWH的抑郁症临床诊断。我们排除了距离先前诊断、抗抑郁药处方少于90天或心理健康就诊次数超过一次的诊断。我们估计了在首次抑郁诊断后1个月内开始使用抗抑郁药与随后3至12个月首次病毒载量时病毒载量未被抑制(>200拷贝/毫升)之间的关联。我们对一系列全面的人口统计学和临床混杂因素进行了调整。
我们纳入了946名患者的2346例抑郁症诊断;16%的患者开始使用抗抑郁药。在未进行抗抑郁药治疗的情况下,病毒未被抑制的风险为15.6%[95%置信区间(CI):13.1 - 18.4]。开始使用抗抑郁药与病毒未被抑制(风险差异:0.5%;95%CI:-3.7至4.8)或次要结局无关:抑郁症状的改善或缓解或按时就诊的依从性。
在这个尚未接受治疗的抑郁症患者样本中,在有共址、低门槛精神科服务的环境中,抗抑郁药治疗与改善病毒抑制无关。抑郁症的药物管理在其他研究中有已记录的益处。然而,可能有一部分患有抑郁症的PWH此前使用抗抑郁药治疗未成功,他们对批准的药物选择反应较小,需要不同的干预措施来改善病毒抑制。